Matthew Gribbin

Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors

Bonnie S. Glisson, Rom S. Leidner, Robert L. Ferris et al. · Clinical Cancer Research · 2020 · 113 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer

Joachim von Pawel, Jimmie H. Harvey, David R. Spigel et al. · Clinical Lung Cancer · 2014 · 97 citations

Medicine, Oncology, Pharmacology +14

Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors

David M. Hyman, Naiyer A. Rizvi, Ronald B. Natale et al. · Clinical Cancer Research · 2018 · 55 citations · Full text

Medicine, Oncology, Pharmacology +16

A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma

Tudor–Eliade Ciuleanu, I. Bazin, Dan Lungulescu et al. · Annals of Oncology · 2016 · 51 citations · Full text

Medicine, Oncology, Pharmacology +14

Brief report: How well do clinic-based blood pressure measurements agree with the mercury standard?

Jennifer W. Kim, Hayden B. Bosworth, Corrine I. Voils et al. · Journal of General Internal Medicine · 2005 · 33 citations

Medicine, Cardiology, Internal Medicine +16